We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy (MIC)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: September 29, 2009
Last Update Posted: December 17, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
To evaluate the safety and preliminary efficacy of intravitreal microplasmin as an adjunct to conventional vitrectomy for the treatment of pediatric patients.

Condition Intervention Phase
Vitrectomy Drug: Ocriplasmin Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The MIC (Microplasmin In Children) Trial: A Randomized, Placebo-controlled, Double-masked, Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy

Resource links provided by NLM:

Further study details as provided by ThromboGenics:

Primary Outcome Measures:
  • Percentage of Eyes With Total Macular Posterior Vitreous Detachment (PVD). [ Time Frame: Beginning of vitrectomy or after application of suction ]
    Percentage of eyes with total macular PVD (to the vascular ridge in eyes with ROP) at the beginning of vitrectomy or after application of suction, as assessed by masked surgeon observation under the operating microscope.

Enrollment: 24
Study Start Date: February 2010
Study Completion Date: April 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ocriplasmin Drug: Ocriplasmin
175µg ocriplasmin intravitreal injection
Placebo Comparator: Placebo Drug: Placebo
Placebo intravitreal injection


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female infants or children 16 years of age or younger
  2. Patient must be a suitable candidate for conventional 2-port or 3-port pars plana vitrectomy
  3. Patient with attached vitreous somewhere in posterior pole
  4. Patient's parent or guardian must be willing and able to comply with follow-up requirements
  5. Patient's parent(s) must sign informed parental permission form and in the case of school-age children the patient must sign assent form

Exclusion Criteria:

  1. Patient diagnosed with Stage 1, 2, 3 or 5 retinopathy of prematurity (ROP) at the time of surgery
  2. Unclear media, which precludes assessment of the posterior pole such as a cataract or vitreal opacity
  3. Active parental/guardian drug or alcohol use or dependence that, in the opinion of the site Investigator, would interfere with parent's or guardian's adherence to study requirements
  4. Medical problems that make consistent follow-up over the treatment period uncertain.
  5. Patient must not have participated in an investigational drug or device study in the prior 30 days
  6. Female Patients of childbearing potential must not be pregnant or lactating.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00986362

United States, Michigan
Associated Retina Consultants
Royal Oak,, Michigan, United States, 48073
Sponsors and Collaborators
  More Information

Responsible Party: ThromboGenics
ClinicalTrials.gov Identifier: NCT00986362     History of Changes
Other Study ID Numbers: TG-MV-009
First Submitted: September 28, 2009
First Posted: September 29, 2009
Results First Submitted: July 4, 2013
Results First Posted: February 20, 2014
Last Update Posted: December 17, 2014
Last Verified: April 2014

Keywords provided by ThromboGenics:
Safety in pediatrics

Additional relevant MeSH terms:
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action